Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $8.92, for a total transaction of $17,840.00. Following the sale, the chief executive officer now owns 14,625,350 shares in the company, valued at $130,458,122. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Thomas Sandgaard also recently made the following trade(s):

• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total value of $17,260.00.

Zynex Stock Performance

Zynex stock traded up $0.13 during midday trading on Friday, hitting $8.76. 132,489 shares of the company’s stock were exchanged, compared to its average volume of 172,354. The firm’s 50 day simple moving average is $8.10 and its 200 day simple moving average is $9.11. Zynex, Inc. has a 12-month low of $7.15 and a 12-month high of $13.77. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The stock has a market cap of $279.01 million, a price-to-earnings ratio of 58.40 and a beta of 0.54.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. The business had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 earnings per share. Equities research analysts predict that Zynex, Inc. will post 0.2 EPS for the current year.

Analyst Ratings Changes

ZYXI has been the topic of a number of recent analyst reports. HC Wainwright increased their price objective on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Royal Bank of Canada decreased their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Hedge Funds Weigh In On Zynex

A number of large investors have recently made changes to their positions in ZYXI. Principal Financial Group Inc. boosted its stake in shares of Zynex by 10.4% during the 2nd quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after acquiring an additional 1,846 shares in the last quarter. Cim LLC raised its stake in shares of Zynex by 6.1% during the 2nd quarter. Cim LLC now owns 43,581 shares of the company’s stock worth $406,000 after buying an additional 2,508 shares during the last quarter. American Century Companies Inc. raised its position in Zynex by 10.1% during the second quarter. American Century Companies Inc. now owns 31,159 shares of the company’s stock worth $290,000 after acquiring an additional 2,864 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Zynex by 1.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 192,832 shares of the company’s stock valued at $1,797,000 after buying an additional 2,954 shares in the last quarter. Finally, Sei Investments Co. lifted its position in shares of Zynex by 32.3% in the second quarter. Sei Investments Co. now owns 21,717 shares of the company’s stock valued at $202,000 after acquiring an additional 5,300 shares in the last quarter. Hedge funds and other institutional investors own 29.68% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.